Alaleh Nouri - Dec 14, 2023 Form 4 Insider Report for PROCEPT BioRobotics Corp (PRCT)

Role
EVP, CLO, CORP. SEC.
Signature
/s/ Jonathan Stone, Attorney-in-Fact for Alaleh Nouri
Stock symbol
PRCT
Transactions as of
Dec 14, 2023
Transactions value $
-$576,061
Form type
4
Date filed
12/15/2023, 06:28 PM
Previous filing
Dec 8, 2023
Next filing
Jan 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRCT Common Stock Options Exercise $14.6K +3.2K +6.83% $4.56 50.1K Dec 14, 2023 Direct F1
transaction PRCT Common Stock Sale -$138K -3.2K -6.39% $42.95 46.9K Dec 14, 2023 Direct F1, F2
transaction PRCT Common Stock Options Exercise $53.8K +11.8K +25.13% $4.56 58.7K Dec 15, 2023 Direct F1
transaction PRCT Common Stock Sale -$507K -11.8K -20.09% $42.97 46.9K Dec 15, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRCT Stock Option (Right to Buy) Options Exercise $0 -3.2K -7.17% $0.00 41.5K Dec 14, 2023 Common Stock 3.2K $4.56 Direct F1, F4
transaction PRCT Stock Option (Right to Buy) Options Exercise $0 -11.8K -28.43% $0.00 29.7K Dec 15, 2023 Common Stock 11.8K $4.56 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 3/7/2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.95 to $42.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.95 to $43.025, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4 The Stock Option was granted on December 12, 2019 and vested over a four year period